Search Results

Showing 107 results

Taxonomy / Categories

GCLLSG 2026

Congress Year

German CLL Studygroup

iwCLL 2025

Congress Year

International Workshop on CLL 2025

CLL

Disease Area

CLL/SLL

Disease Area

CLL

Congress Disease State

CLL/SLL

Congress Disease State

R/R CLL

Congress Disease State

Treatment Naive CLL/SLL

Congress Disease State

Updated safety and efficacy of all oral sonrotoclax + zanubrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p)/TP53

Congress Resource

BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A Phase 1 CaDAnCe-101 study update

Congress Resource

Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the Phase 1 CaDAnCe-101 study

Congress Resource

Managing infection risks in CLL | Helen Parry

Congress Resource

Satellite Symposium – Navigating treatment selection and infection management in CLL

Congress Resource

Panel discussion: Addressing key questions in CLL management | All faculty

Congress Resource

Navigating treatment selection and infection management in CLL | Summary

Congress Resource

ASH 2023 updates: ALPINE study of zanubrutinib vs. ibrutinib in R/R CLL

Disease Education

ASH 2023 updates: BTK inhibitor monotherapy for treatment-naive CLL

Disease Education

BeiGeneius Hematology Summit – Relapsed/refractory CLL and indolent lymphomas

Disease Education

A multidisciplinary panel review the latest developments in R/R CLL and indolent lymphomas and share expert overviews of clinical trial interpretation and best practice in patient communication.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed